NEW YORK, Sept. 11 – In a move that brings it a step closer to its goal of becoming a global pharmaceutical company, gene-based drug discovery company Human Genome Sciences (Nasdaq: HGSI) said Monday it had acquired privately held Principia Pharmaceutical for about $120 million in stock.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.